22:16 ETGroundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicineprnewswire·Jul 8 at 09:18 PM300558-0.19%
BETTA PHARMACEUTICALS: The company currently does not have exclusive agency for foreign productsZhitong·Oct 17, 2025 at 03:33 AM贝达药业300558-0.19%
A-share innovative drug concept stocks fluctuated lower, with BETTA PHARMACEUTICALS falling over 10%, Jincheng Pharm, Konruns, Baillie Tianheng, Olymvax Biopharmaceuticals, and CCHT all dropping more than 5%Zhitong·Oct 14, 2025 at 01:11 AM300233+1.99%000661+1.97%
BETTA PHARMACEUTICALS: Will strive for more new drug approvals in high-incidence tumor areas such as lung cancer and breast cancerWallstreetcn·Sep 2, 2025 at 08:30 PM300558-0.19%贝达药业
BETTA PHARMACEUTICALS: The first prescription for Enasidenib Hydrochloride Capsules has been issued in the United StatesZhitong·Aug 27, 2025 at 05:40 AM贝达药业300558-0.19%
BETTA PHARMACEUTICALS: Clinical research on the postoperative adjuvant indication of ensartinib has made progressZhitong·Aug 24, 2025 at 07:04 PM贝达药业300558-0.19%
BETTA PHARMACEUTICALS: Currently, there is no need to provision for the issuance loss of Heyuan BiotechnologyZhitong·Aug 24, 2025 at 01:50 AM300558-0.19%贝达药业
BETTA PHARMACEUTICALS released its performance for the first half of the year, with a net profit attributable to the parent company of 140 million yuan, a decrease of 37.53%Zhitong·Aug 19, 2025 at 05:59 AM贝达药业300558-0.19%
BETTA PHARMACEUTICALS: MCLA-129 is currently exploring indications in the field of lung cancerZhitong·Aug 18, 2025 at 11:47 PM300558-0.19%贝达药业
BETTA PHARMACEUTICALS: The company has corresponding preclinical project establishment for the KRAS targetZhitong·Jul 19, 2025 at 05:04 AM300558-0.19%贝达药业
BETTA PHARMACEUTICALS: Has reached a strategic cooperation with Boryung Biopharma, and the company’s exclusive distribution of Anruize has officially launched nationwide salesZhitong·Jul 14, 2025 at 07:50 AM贝达药业300558-0.19%
BETTA PHARMACEUTICALS: The company is accelerating the overseas commercial plan for ensartinibZhitong·Jul 4, 2025 at 03:45 AM300558-0.19%贝达药业
BETTA PHARMACEUTICALS: The Macao Drug Regulatory Authority has approved the marketing of Enasidenib Hydrochloride CapsulesZhitong·Jul 2, 2025 at 04:15 AM贝达药业300558-0.19%
